Pfizer and BioNTech have officially submitted a request to have their COVID-19 vaccine authorized for younger children, according to Health Canada.
The vaccine, marketed under the name ‘Comirnaty,’ is currently offered to Canadians as young as 12.
If approved, it would become available to children as young as five.
“As with all COVID-19 vaccines, the Department will prioritize the review of this submission, while maintaining its high scientific standards for safety, efficacy and quality,” reads a statement by Health Canada.
This could make Pfizer-BioNTech’s vaccine the first to be approved for young children in Canada. The companies have previously tested a lower dose of the vaccine on children, saying they’ve noticed similarly-strong antibody responses as those in teens and young adults.
“Health Canada will only authorize the use of Comirnaty if the independent and thorough scientific review of all the data included in the submission showed that the benefits of the vaccine outweighed the potential risks in this age group,” continues the statement. “The assessment will include a detailed review of clinical trial results, as well as other evolving data and information about the health impacts of COVID-19 and variants of concern on children in Canada.”
Photo courtesy of BioNTech